drugset / Trial / NCT04327206

BCG Vaccination to Protect Healthcare Workers Against COVID-19

NCT04327206

RandomizedParallel-groupDouble-blindPrevention

Summary

Phase III, two-group multicentre, randomised controlled trial in up to 10 078 healthcare workers to determine if BCG vaccination reduces the incidence and severity of COVID-19 during the 2020 pandemic.

Timeline

Start
2020-03-30
Primary completion
2021-11-10
Completion
2022-05-27

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject BCG vaccine Vaccine 0.1 ml Intrathecal